Provided by Tiger Trade Technology Pte. Ltd.

GT Biopharma Inc.

0.3058
+0.01725.96%
Pre-market: 0.2900-0.0158-5.17%04:17 EDT
Volume:644.30K
Turnover:193.43K
Market Cap:13.79M
PE:-0.58
High:0.3180
Open:0.2901
Low:0.2851
Close:0.2886
52wk High:1.37
52wk Low:0.2610
Shares:45.11M
Float Shares:42.52M
Volume Ratio:1.70
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5288
EPS(LYR):-6.9370
ROE:-113.52%
ROA:-158.16%
PB:3.87
PE(LYR):-0.04

Loading ...

Company Profile

Company Name:
GT Biopharma Inc.
Exchange:
NASDAQ
Establishment Date:
1965
Employees:
1
Office Location:
315 Montgomery Street,10th Floor,San Francisco,California,United States
Zip Code:
94104
Fax:
- -
Introduction:
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Directors

Name
Position
Michael Breen
Chief Executive Officer, Director and Executive Chairman of the Board
Charles J. Casamento
Director
David C. Mun Gavin
Director
Hilary Kramer
Director

Shareholders

Name
Position
Michael Breen
Chief Executive Officer, Director and Executive Chairman of the Board
Alan Urban
Chief Financial Officer and Secretary